Trendlines Group

Trendlines appointed agrifood tech co-investor by Enterprise Singapore's Seeds Capital

SINGAPORE (Jan 16): Trendlines Group says its new US$40 million Singapore venture fund ($54.2 million) has been appointed as a partner under the Startup SG Equity scheme, which is administered by Enterprise Singapore investment arm Seeds Capital.

To recap, Seeds Capital issued a call for proposals for potential partners to co-invest in the agrifood tech field in Sept 2018.

Trendlines remains undervalued and 'overweight': NRA

SINGAPORE (June 28): NRA Capital is reiterating its “overweight” recommendation on Trendlines Group with a fair value estimate of 22.5 cents.

The group organised a “meet the senior management” session yesterday at the JTC Launchpad, which saw over 70 people participating, including individual and institutional investors.

At the event, the group CEOs and six key executives, including the CEOs of Trendlines Incubators Israel and Trendlines Labs and the group’s VP of business development, answered questions fielded by investors and shareholders in a panel discussion.

Trendlines receives FDA regulatory clearance for meniscus repair system

SINGAPORE (June 19): Trendlines Group announced that its portfolio company, Arcuro Medical, has received regulatory clearance from the United States Food and Drug Administration (FDA) for its SuperBall meniscus repair system.

This comes after Arcuro completed an extensive and successful series of pre-clinical studies in the US and Israel.

Superball is an all-suture meniscus repair system that preserves knee functionality that is secure, reliable, and effective.

Trendlines' Saturas completes investment round of US$4 mil

SINGAPORE (Feb 26): Trendlines announced that its portfolio company Saturas has completed an investment round of US$4 million ($5.27 million).

Saturas is developing an Advanced Decision Support System (ADSS) for automatic irrigation based on its miniature stem water potential (SWP) sensor.

Embedded in the trunks of trees, vines, and plants, Saturas’ sensors receive direct input from the tree or vine to provide real-time, accurate and continuous information for optimised irrigation.

Trendlines teams up with Ozi Amanat as Startup SG Equity co-investors

SINGAPORE (Feb 8): Trendlines Medical Singapore, a subsidiary of Israeli company The Trendlines Group, is partnering Singapore-based investor Ozi Amanat’s venture capital firm, K2 Global, to collaborate in SPRING SEEDS Capital’s (SSC) $100 million investment allocation via the Startup SG Equity scheme.

Under the Startup SG Equity scheme, SSC supports early-stage startups across the technology and industry domain areas, and catalyses private-sector investments for startups via government equity co-investment.

Finally, some good news for long-suffering Trendlines investors

SINGAPORE (Dec 8): The Trendlines Group’s announcement at end-October that it will start paying dividends in the next financial year could boost returns for long-suffering shareholders of the medical technology incubator.

Those who bought into the stock at its IPO in November 2015 have seen the value of their investments more than halve since.

Trendlines Medical makes maiden investment in medical device startup

SINGAPORE (Oct 16): Trendlines Medical Singapore, a 76.43%-owned subsidiary of Catalist-listed Israeli company The Trendlines Group, has made its first investment by committing a total of US$60,000 ($81,150) to a medical device start-up, InterVaal.

InterVaal is developing a urological catheter to address catheter associated urinary tract infection.

Trendlines says that its in-house innovation unit, Trendlines Labs, will work with InterVaal’s Singapore-based staff to develop the catheter and conduct clinical trials in Singapore.

Trendlines in private placement to raise $14 mil

SINGAPORE (Oct 10): Trendlines Group, the investor, incubator and developer of early-stage medical and agricultural startup in Israel is raising net proceeds of $13.34 million by placing out 100 million new shares at 14.03 cents each.

In its filing, Trendlines says the placement price represents a discount of 9.95% to the volume weighted average price of 15.58 cents for each share on Tuesday. The 100 million new shares also represent a 16.43% stake in the enlarged share capital of Trendlines.

Trendlines to sell entire 6% stake in MitrAssist Medical for US$1.15 mil

SINGAPORE (Aug 30): A subsidiary of Trendlines Group is disposing its entire 6% stake in MitrAssist Medical for a consideration of US$1.15 million ($1.55 million).

Wholly owned subsidiary Trendlines Incubators Israel is selling the stake in MitrAssist Medical to Wai Tech (Hong Kong).

Trendlines Incubators Israel currently holds 328,156 MitrAssist shares as well as options to purchase another 45,637 shares.

Wai Tech is an existing shareholder of MitrAssist holding about a 61% stake.

Trendlines joint fund establishes new company to research crop protection

SINGAPORE (June 27): Trendlines Group, the Catalist-listed innovation commercialisation company based in Israel, has announced that its Bayer Trendlines Ag Innovation Fund will be establishing a new company, ABI-Ag, to conduct specific research in the field of crop protection.

This is the first investment made by the innovation fund since it was set up in 2016 as a partnership between the group and global enterprise Bayer. The fund includes a US$10 million ($13.9 million) investment from the latter.

Be informed of the stories that matter